OakChart

Aptevo Therapeutics Inc

APVOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.7600-0.3200 (-29.63%)
2026-11-12 00:44 CET
Market cap
1.96 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-28.08 USD m
Free cash flow, TTM
-25.34 USD m
EPS diluted, TTM
-57.76
P/E
-
Compare

Price

APVO against its 20, 50 and 200-day averages
2050200beat
0.005.0010.0015.00845K1.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26APVOclose 0.7620-day 1.3850-day 1.65200-day 4.050.76

97.3% under the 52-week high of 27.72 on 13 Nov 2025. 52-week low 0.74 on 11 Nov 2026. Last 15 sessions, 135.1% high to low

Volume 6.09× normal · the line is the 50-bar volume average

Profile

APVO
52-week range, 0% of the way up
1.0727.72

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Employees36
IPOJul 20, 2016
Beta1.63
ATR, 14d0.14
Rel volume6.09
Short float4.19%
Insider own5.81%
Inst own3.29%

Snapshot

6 groups

Valuation

Index-
Market Cap1.38M
Enterprise Value-4.21M
Income-28.08M
Sales0.00M
Book/sh4.26
Cash/sh5.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees36
IPOJul 20, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.18
P/C0.14
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.08
Current Ratio2.08
Debt/Eq0.70
LT Debt/Eq0.54
Option/ShortNo / Yes

Earnings

EPS (ttm)-57.76
EPS next Y-6.59
EPS next Q-3.71
EPS this Y80.47%
EPS next Y61.33%
EPS next 5Y58.56%
EPS past 3/5Y- 89.05%
Sales past 3/5Y- -
EPS Y/Y TTM99.41%
Sales Y/Y TTM-
EPS Q/Q96.49%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.11.72% -

Ownership

Insider Own5.81%
Insider Trans0.00%
Inst Own3.29%
Inst Trans2.61%
ROA-185.67%
ROE-445.43%
ROIC-299.90%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-45.12%
SMA50-54.07%
SMA200-81.25%
Trades-

Technical

Shs Outstand1.81M
Shs Float1.70M
Short Float4.19%
Short Ratio0.71
Short Interest0.07M
52W High27.72 -97.26%
52W Low1.07 -28.97%
Volatility12.41% 8.74%
ATR (14)0.14
RSI (14)13.18
Beta1.63
Rel Volume6.09
Avg Volume99.70K
Volume607,624

Performance

Perf Week-44.53%
Perf Month-56.07%
Perf Quarter-77.65%
Perf Half Y-84.03%
Perf YTD-91.94%
Perf Year-97.19%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price25.50
Prev Close1.08
Price0.76
Change %-29.63%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Nov 05, 2018InitiatedLLadenburg ThalmannBuy
Oct 05, 2017ResumedPPiper JaffrayOverweight$6+689.5%

Peers

Mkt cap
TickerCompanyMkt cap
GTBPGT Biopharma Inc8.14M
HCWBHCW Biologics Inc1.92M
XLOXilio Therapeutics Inc55.74M
HOWLWerewolf Therapeutics Inc48.06M
MGNXMacrogenics Inc147.78M
JANXJanux Therapeutics Inc758.06M
ATNMActinium Pharmaceuticals Inc49.99M
CUECue Biopharma Inc135.55M
CTMXCytomX Therapeutics Inc464.35M
TCRTAlaunos Therapeutics Inc6.65M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100
  • Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds (ACCESSWIRE) -29.63%
  • Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors (ACCESSWIRE) -8.87%
  • Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML (ACCESSWIRE) -7.30%
  • Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant (ACCESSWIRE) -6.83%
  • Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting (ACCESSWIRE)
  • Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development (ACCESSWIRE)
  • Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML (InvestorsHub) -34.23%
  • Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML (ACCESSWIRE)
  • Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results (ACCESSWIRE) -13.53%
  • Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds (ACCESSWIRE)
  • Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds (ACCESSWIRE) -15.38%
  • Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone (ACCESSWIRE)
  • Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors (ACCESSWIRE)
  • Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-5.310-6.015-5.3100.000.002
2026Q12026-05-07-6.410-5.600-6.4100.000.001
2025Q42026-03-261,684-5.940-5.9110.000.001
2025Q32025-11-06-40.140-37.620-40.1340.000.001
2025Q22025-08-11-151.2--151.290.00--
2025Q12025-05-15-1,580-1,516-1,5820.000.001
2024Q42025-02-14-3,218-2,790-1,5580.000.001
2024Q32024-11-07-6,394-7,592-6,4410.000.001
2024Q22024-08-08-22,244-25,708-22,2630.000.001
2024Q12024-05-08-132,534-143,456-132,5530.000.002
2023Q42024-03-06-178,888-263,736-177,7050.000.001
2023Q32023-11-15-293,040-375,091-295,1150.000.002
2023Q22023-08-10-720,878-656,410-718,6100.000.001
2023Q12023-05-11152,381-694,505231,4370.000.002
2022Q42023-03-30-621,245-896,702-420,7350.000.002
2022Q32022-11-11-898,109-955,310-880,0520.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-8,553,838-8,779,478-125,727,79332.4232.66
2020FY-5,345,050-3,637,623-5,546,0284.314.15
2021FY-3,674,722-3,598,531-3,557,64612.2912.03
2022FY802,930545,054921,9163.113.11
2023FY-20,304-1,641,024-834,0450.000.00
2024FY-31,457-30,946-31,4580.000.00
2025FY-87.270-87.270-87.2700.000.00
2026FY--17.040--0.00
2027FY--6.590--0.00
2028FY--6.210--0.00
2029FY--2.210--21.34
2030FY-10.090--66.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-06-162000.000.000.00
2026Q3S2026-05-071000.000.000.00
2026Q3S2026-03-261000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00

Estimate history

EPS, annual-17584638.952-19578811.331-125727793.124-5546028.174-3557646.272921915.565-834044.59-31458.298-87.274-57.7628
Period201720182019202020212022202320242025TTM
EPS, quarterly-22262.648-6441.286-1558.044-1581.725-151.287-40.134-5.911-6.405-5.313
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual14.65823.06704.30912.2923.1140000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00000000.0040.9981.419
Period201720182019202020212022202320242025MRQ
Shares, quarterly00.0010.0040.0040.1790.7670.9981.2041.419
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.003.1112.294.310.0023.07
Cost of Goods Sold Incl. D&A0.200.240.350.570.90--2.2311.21
Gross Profit-0.20-0.24-0.35-0.572.21---2.2311.85
Selling, General and Administrative Excl. Other26.6926.0724.2528.3130.8532.5530.4038.7363.52
Research and Development15.0014.3014.0316.5416.9817.8516.4524.7635.38
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.89-26.31-24.60-28.88-28.64-21.40-27.49-40.96-51.66
Interest Expense0.000.000.00------
Unusual Expense0.000.000.000.00-39.680.002.100.00-
Net Income Before Taxes-26.41-25.97-24.13-18.657.01-29.41-30.92-43.06-53.69
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-27.98-25.97-24.13-18.657.01-29.41-30.92-43.06-53.69
Net Income From Continuing Operations-27.98-25.97-24.13-18.657.01-29.41-30.92-43.06-53.69
Net Income-28.08-27.54-24.13-17.418.03-28.46-32.09-44.70-53.69
EPS (Recurring)-23.47-87.27-31,458.30-834,043.45-2,268,373.42-3,557,645.31-5,291,474.24-125,729,234.06-19,578,805.34
EPS (Basic, Before Extraordinaries)-57.76-87.27-31,458.30-834,044.59922,390.29-3,557,646.27-5,546,028.17-125,727,793.12-19,578,811.33
EPS (Diluted)-57.76-87.27-31,458.30-834,044.59921,915.56-3,557,646.27-5,546,028.17-125,727,793.12-19,578,811.33
EBITDA-26.69-26.07-24.25-28.31-27.74-20.26-26.09-38.73-49.27
Non-Operating Income (Expense)0.480.340.4710.23-4.03-8.01-1.32-2.10-2.02
Other After Tax Adjustments-1.580.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.190.101.072.191.801.641.251.602.14
Price To Earnings Ratio----1.88----
Price To Sales Ratio----3.803.0028.840.821.24
Gross Margin----71.07---51.39
Operating Margin-----919.75-174.10-638.06--223.98
Net Margin----257.77-231.51-744.67--232.75
Shares Outstanding1.421.000.000.000.000.000.000.000.00
Market Capitalization1.961.966.292.6211.8138.55161.6629.6428.97

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.040.080.050.050.060.070.00
Gross Profit-0.03-0.04-0.08-0.05-0.05-0.06-0.070.00
Selling, General and Administrative Excl. Other6.416.805.927.566.186.426.315.21
Research and Development3.663.893.454.003.283.573.813.10
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.44-6.84-6.00-7.61-6.23-6.48-6.38-5.21
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-6.36-6.70-5.81-7.55-6.20-6.41-6.31-5.10
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.36-6.79-5.81-9.03-6.20-6.41-6.31-5.10
Net Income From Continuing Operations-6.36-6.79-5.81-9.03-6.20-6.41-6.31-5.10
Net Income-6.36-6.79-5.90-9.03-6.20-6.41-6.31-5.10
EPS (Recurring)-5.31-6.41-5.91-40.13-151.29-1,581.73-1,558.05-6,441.25
EPS (Basic, Before Extraordinaries)-5.31-6.41-5.91-40.13-151.29-1,581.72-1,558.04-6,441.29
EPS (Diluted)-5.31-6.41-5.91-40.13-151.29-1,581.72-1,558.04-6,441.29
EBITDA-6.41-6.80-5.92-7.56-6.18-6.42-6.31-5.13
Non-Operating Income (Expense)0.090.140.190.060.020.070.070.11
Other After Tax Adjustments0.00-0.100.00-1.480.000.000.000.00
Stock Option Compensation Expense0.060.060.000.08-0.160.18-0.15
Shares Outstanding1.421.201.000.770.180.000.000.00
Market Capitalization1.965.058.8320.029.831.696.293.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments21.628.7116.9022.6446.3042.5312.4530.6481.18
Short Term Receivables0.000.000.002.503.662.370.005.222.14
Inventories0.000.000.000.000.000.000.001.781.03
Other Current Assets1.461.952.162.312.602.3617.5511.0510.73
Total Current Assets23.0810.6619.0727.4552.5747.2630.0048.6995.08
Net Property, Plant & Equipment4.114.935.786.763.965.547.695.205.84
Total Investments and Advances0.000.000.000.000.000.007.507.4510.00
Intangible Assets0.000.000.000.00--4.425.256.08
Deferred Tax Assets0.80--------
Other Assets0.000.000.000.000.070.758.220.910.00
Total Assets27.9915.5924.8434.2256.6053.5553.4167.49117.01
Short Term Debt Incl. Current Port. of LT Debt0.870.000.003.1625.555.6119.860.003.33
Accounts Payable0.883.053.983.503.465.586.4311.677.35
Other Current Liabilities4.313.153.242.055.753.3511.955.947.83
Total Current Liabilities6.056.217.228.7134.7614.5438.2417.6118.51
Long Term Debt3.764.635.407.5420.6322.413.3319.2815.73
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.80--------
Other Liabilities0.000.000.000.000.000.000.000.200.73
Total Liabilities10.6110.8412.6216.2455.3836.9541.5737.0934.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity17.384.7512.2217.971.2216.5911.8430.4182.03
Total Shareholders Equity17.384.7512.2217.971.2216.5911.8430.4182.03
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity17.384.7512.2217.971.2216.5911.8430.4182.03
Total Liabilities & Stockholders Equity27.9915.5924.8434.2256.6053.5553.4167.49117.01
Book Value Per Share17.421,173.72367,907.211,629,094.19145,498.672,204,854.2730,042,874.9010,938,281.7031,154,117.78
Tangible Book Value Per Share17.421,173.72367,907.211,629,094.19145,498.752,204,854.5630,042,874.909,049,637.0228,845,131.40
Full-Time Employees36424045545880118121
Price to Book Ratio0.251.320.180.7531.709.742.500.951.01
Return on Assets-119.16-119.36-63.1615.45-53.40-57.82-71.24-58.20-31.21
Return on Equity-234.61-284.28-123.5373.10-330.24-217.49-203.86-95.50-49.16
Return on Invested Capital-122.81-257.14-98.8331.47-130.27-82.26-294.67-108.06-46.77
Quick Ratio3.821.722.643.151.513.250.782.665.08
Current Ratio3.821.722.643.151.513.250.782.765.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-26.41-25.97-24.13-17.418.03-28.46-17.75-40.45-53.69
Depreciation0.200.240.350.570.901.141.412.232.39
Other Funds (Non Cash)1.821.191.072.20-32.098.29-10.57-1.982.53
Funds from Operations-24.39-24.54-22.71-14.64-23.17-19.02-26.91-40.19-48.77
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.96-1.05-1.082.912.14-2.65-2.41-2.19-3.25
Cash from Operating Activities-25.34-25.59-23.79-11.73-21.02-21.68-29.32-42.38-52.02
Capital Expenditures0.000.000.000.00-0.03-0.71-0.09-0.15-0.98
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.0028.124.250.07
Purchase or Sale of Investments0.000.000.000.000.000.000.000.0073.71
Purchase of Investments0.000.000.000.000.000.000.000.00-16.54
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.0090.24
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.03-0.7128.034.1072.80
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock25.7338.5015.609.476.9311.4421.2620.340.62
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock25.7338.5015.609.476.9311.4421.2620.340.62
Proceedsfrom Stock Options0.000.000.000.006.9310.230.000.000.00
Issuance or Reduction of Debt, Net0.000.000.00-3.47-19.0514.722.63-0.140.00
Change in Long Term Debt0.000.000.00-3.47-19.0514.720.00-0.140.00
Issuance of Long Term Debt0.000.000.000.000.0035.000.000.000.00
Reduction of Long Term Debt0.000.000.00-3.47-19.05-20.280.00-0.140.00
Net Financing Active Other Cash Flow-0.000.00-0.00-0.019.500.00-0.01-0.06-0.81
Other Financing Activities Uses-0.000.00-0.00-0.01-0.500.00-0.01-0.06-0.81
Cash from Financing Activities25.7338.5015.606.00-2.6226.1623.8720.15-0.18
Net Change in Cash0.3912.90-8.19-5.73-23.673.7722.59-18.1420.59
Free Cash Flow-25.34-25.59-23.79-11.73-21.05-22.39-29.41-42.54-53.00
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments9.8014.5321.6221.069.412.14
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.001.461.461.591.671.47
Total Current Assets10.8015.9823.0822.6511.083.61
Net Property, Plant & Equipment3.723.924.114.354.544.74
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.80---
Other Assets0.000.000.000.000.000.00
Total Assets14.5219.9027.9927.0015.628.34
Short Term Debt Incl. Current Port. of LT Debt0.920.890.870.000.000.00
Accounts Payable1.160.890.882.222.903.79
Other Current Liabilities3.112.984.313.401.991.60
Total Current Liabilities5.194.766.055.614.895.39
Long Term Debt3.293.533.763.994.214.42
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.80---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities8.488.2910.619.609.109.81
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.0411.6117.3817.396.52-1.47
Total Shareholders Equity6.0411.6117.3817.396.52-1.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.0411.6117.3817.396.52-1.47
Total Liabilities & Stockholders Equity14.5219.9027.9927.0015.628.34
Book Value Per Share4.269.6517.4222.6736.42-363.58
Tangible Book Value Per Share4.269.6517.4222.6736.42-363.58
Full-Time Employees--36---
Price to Book Ratio0.250.250.421.151.51-1.15
Return on Assets-185.67-197.08-125.94-132.66-157.31-182.54
Return on Equity-445.43-549.01-247.98-256.30-437.34-1,023.93
Return on Invested Capital-68.12-44.87-27.46-42.22-57.80-217.29
Quick Ratio2.083.363.824.032.270.67
Current Ratio2.083.363.824.032.270.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.36-6.70-5.81-7.55-6.20-6.41
Depreciation0.030.040.080.050.050.06
Other Funds (Non Cash)0.330.331.090.08-0.160.18
Funds from Operations-6.00-6.33-4.63-7.42-6.32-6.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.54-1.63-0.600.73-0.78-0.41
Cash from Operating Activities-5.45-7.96-5.24-6.69-7.09-6.58
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00-0.000.000.00
Change in Capital Stock0.730.875.7918.3414.360.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.730.875.7918.3414.360.00
Proceedsfrom Stock Options-0.870.870.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.000.000.000.000.00
Other Financing Activities Uses0.00-0.000.000.000.000.00
Cash from Financing Activities0.730.875.7918.3414.360.00
Net Change in Cash-4.73-7.090.5611.657.27-6.58
Free Cash Flow-5.45-7.96-5.24-6.69-7.09-6.58

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.19%0.1M1.7M95.55K
2026-10-155.68%0.1M1.7M92.84K
2026-09-307.03%0.1M1.7M111.69K
2026-09-1511.06%0.2M1.7M104.88K
2026-08-316.95%0.1M1.7M56.04K
2026-08-144.95%0.1M1.7M50.66K
2026-07-316.26%0.1M1.4M55.91K
2026-07-1511.93%0.1M1.2M56.15K
2026-06-306.91%0.1M1.2M36.23K
2026-06-156.41%0.1M1.3M39.09K
2026-05-296.41%0.1M1.3M53.72K
2026-05-157.03%0.1M1.3M52.68K
2026-04-307.81%0.1M1.2M50.63K
2026-04-158.83%0.1M1.2M60.23K
2026-03-3111.28%0.1M1.2M174.71K
2026-03-1311.20%0.1M1.0M189.68K
2026-02-2711.68%0.1M1.0M179.71K
2026-02-1313.35%0.1M1.0M181.76K
2026-01-3015.22%0.2M1.0M181.29K
2026-01-1523.40%0.2M0.9M174.70K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-30424B5SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-09-25S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-238-KCurrent report2026-09-22SEC
2026-09-03424B4SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-09-02EFFECTEffectiveness filing by commission orderSEC
2026-08-31CORRESPSEC
2026-08-31DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-22SEC
2026-08-27UPLOADUpload SubmissionSEC
2026-08-26DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-21PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-21SEC
2026-08-21S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-138-KCurrent report2026-08-12SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1120.13K100

Institutional holders

Manager% owned
GSA CAPITAL PARTNERS LLP1.73%
VANGUARD CAPITAL MANAGEMENT LLC1.02%
GEODE CAPITAL MANAGEMENT, LLC0.87%
VANGUARD FIDUCIARY TRUST CO0.33%
UBS Group AG0.06%
OSAIC HOLDINGS, INC.0.03%
SBI Securities Co., Ltd.0.01%
BARCLAYS PLC0.00%
Caitong International Asset Management Co., Ltd0.00%
DANSKE BANK A/S0.00%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.02%
Fidelity Extended Market Index Fund0.35%
Fidelity Series Total Market Index Fund0.09%

OakChart. APVO. Cached 15 minutes.

Some panels did not load: insider.